NCT02322749 - A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Healthy Volunteers Bioequivalence or Bioavailability Study

Interventions

DRUG

selumetinib 75mg single dose

3 blue capsules of 25 mg given as a single dose

DRUG

selumetinib 75mg single dose

3 capsules of 25 mg given as a single dose

DRUG

selumetinib 75mg single dose

3 capsules of 25 mg given as a single dose

Trial Locations (1)

Research Site, London